Novartis Aktie

93,56 EUR -0,45 EUR -0,48 %

15:25:08

L&S

87,04 CHF -1,00 CHF -1,14 %

17:39:30

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.184,44 Mrd. EUR

KGV13,21Div. Rendite3,89%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

17.12.24ZacksAre Investors Undervaluing Novartis (NVS) Right Now?

13.12.24ZacksReasons to Retain Alcon Stock in Your Portfolio for Now

13.12.24ZacksThe Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology

WerbungNovartis-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

12.12.24ZacksTop Stock Reports for Mastercard, Procter & Gamble & Novartis

10.12.24GlobeNewswireLonger-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

10.12.24Dow JonesPress Release: Longer-term Novartis Kisqali(R) -3-

10.12.24Dow JonesPress Release: Longer-term Novartis Kisqali(R) -2-

10.12.24Dow JonesPress Release: Longer-term Novartis Kisqali(R) NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast ca...

09.12.24ZacksNovartis Announces Positive Results From Late-Stage Study on Fabhalta

08.12.24GlobeNewswireLonger-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

06.12.24BenzingaNovartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

06.12.24ZacksWhy Alcon (ALC) is a Top Growth Stock for the Long-Term

06.12.24GlobeNewswireNew Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

06.12.24Dow JonesPress Release: New Phase IIIB data shows Novartis -2-

06.12.24Dow JonesPress Release: New Phase IIIB data shows Novartis Fabhalta(R) improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switc...

04.12.24ZacksWhy Novartis (NVS) is a Top Growth Stock for the Long-Term

03.12.24ZacksNovartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

02.12.24BenzingaPTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

02.12.24PR NewswirePTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

02.12.24ZacksThe Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis

27.11.24GlobeNewswireNovartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence

27.11.24Dow JonesPress Release: Novartis Kisqali(R) receives -3-

27.11.24Dow JonesPress Release: Novartis Kisqali(R) receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of...

25.11.24GlobeNewswireNovartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

25.11.24Dow JonesPress Release: Novartis highlights new 96-week -2-

25.11.24Dow JonesPress Release: Novartis highlights new 96-week results from Phase III Scemblix(R) ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali(R)...

22.11.24ZacksNovartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

21.11.24BenzingaNovartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline

21.11.24GlobeNewswireNovartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

21.11.24Dow JonesPress Release: Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

19.11.24GlobeNewswireNovartis ranks first in 2024 Access to Medicine Index

18.11.24ZacksAlcon (ALC) is a Top-Ranked Value Stock: Should You Buy?

18.11.24PR NewswireRatio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.